Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...